• First author for breakthrough paper in the leading microfluidics journal, Nature Scientific Report Journal. Article Title: Microfluidic transfection of mRNA into Human Primary Lymphocytes and Hematopoietic Stem and Progenitor Cells using Ultra-fast Physical Deformation• Led rare lymphocyte research and development pipeline for the company with focuses on Natural Killer (NK) Cells, Gamma Delta T Cells, and Peripheral Blood Mononuclear Cells using CellFE’s proprietary technology. Payloads consisted of mRNA CAR delivery, CRISPR/CAS 9 knock-out & knock-in work.• Submitted abstracts for top conferences regarding the rare lymphocyte/cell and gene therapy research field. Expected to get first publication in conferences by the end of May, with more throughout the year.• Created a cost-efficient and scalable Cell Bank that has currently saved the company over 400,000 USD and is projected to save over $1M by 2023• Set up, maintained, and managed the cell supply chain for all workstreams with capacity of up to 8 billion cells/week.• Performed outreach and managed relationships with 20+ vendors to source and procure laboratory components for all pipelines

* Successfully led $300,000 mRNA CAR PBMC NCI Phase 1 grant, contract number 75N91020C00028, from inception to completion. Planned, executed, performed experiments, and analyzed the three objectives of the grant in a timely and cost- efficient manner.• Author of Patent WO2020232418A1 - Intracellular Delivery. Invented methods and systems for cell processing, including delivery of substances into cells comprising the use of a microfluidic device.• Led, designed, and analyzed research regarding Natural Killer (NK) and other rare lymphocytes (including but not limited to Gamma Delta T, Naïve T, and PBMCs) to provide proof of concept with CellFE’s microfluidics technology• Conducted extensive research, sourced data from multiple workstreams, and performed experiments to publish the first research paper for CellFE Inc displaying high success delivery of mRNA across T, Stem, and NK cells without being detrimental to cell health and viability